Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:AURA NASDAQ:AUTL NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.20+2.8%$2.01$1.33▼$3.58$100.86M0.75103,088 shs129,576 shsAURAAura Biosciences$6.48+0.9%$6.64$4.34▼$12.38$398.81M0.45132,623 shs139,848 shsAUTLAutolus Therapeutics$1.46+0.7%$2.14$1.11▼$5.00$385.90M1.873.41 million shs8.77 million shsKMDAKamada$7.14+1.1%$7.39$5.17▼$9.15$405.99M0.8945,346 shs129,797 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-1.83%-3.60%+12.39%+7.54%-25.17%AURAAura Biosciences+1.26%-0.16%-3.17%-1.23%-16.51%AUTLAutolus Therapeutics+0.69%-7.64%-38.82%-38.03%-64.63%KMDAKamada+1.29%+0.57%+3.07%+3.07%+29.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.20+2.8%$2.01$1.33▼$3.58$100.86M0.75103,088 shs129,576 shsAURAAura Biosciences$6.48+0.9%$6.64$4.34▼$12.38$398.81M0.45132,623 shs139,848 shsAUTLAutolus Therapeutics$1.46+0.7%$2.14$1.11▼$5.00$385.90M1.873.41 million shs8.77 million shsKMDAKamada$7.14+1.1%$7.39$5.17▼$9.15$405.99M0.8945,346 shs129,797 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-1.83%-3.60%+12.39%+7.54%-25.17%AURAAura Biosciences+1.26%-0.16%-3.17%-1.23%-16.51%AUTLAutolus Therapeutics+0.69%-7.64%-38.82%-38.03%-64.63%KMDAKamada+1.29%+0.57%+3.07%+3.07%+29.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$7.00218.18% UpsideAURAAura Biosciences 3.11Buy$22.00239.51% UpsideAUTLAutolus Therapeutics 3.00Buy$9.12524.66% UpsideKMDAKamada 2.67Moderate Buy$13.0082.07% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, AUTL, KMDA, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025AURAAura BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/13/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/13/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $5.008/6/2025ADAGAdageneLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025ADAGAdageneLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.007/21/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K1,036.86N/AN/A$1.14 per share1.93AURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AAUTLAutolus Therapeutics$10.12M38.40N/AN/A$1.61 per share0.91KMDAKamada$169.52M2.42$0.50 per share14.36$4.51 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/AN/AAURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)AUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)KMDAKamada$14.46M$0.3421.0022.310.7511.22%7.41%5.18%11/12/2025 (Estimated)Latest ADAG, AUTL, KMDA, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A8/13/2025Q2 2025KMDAKamada$0.09$0.13+$0.04$0.13$158.59 million$44.75 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.292.30AURAAura BiosciencesN/A12.3912.39AUTLAutolus TherapeuticsN/A8.438.07KMDAKamadaN/A4.002.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%AURAAura Biosciences96.75%AUTLAutolus Therapeutics72.83%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%AURAAura Biosciences6.30%AUTLAutolus Therapeutics25.70%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.13 million37.14 millionNot OptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableADAG, AUTL, KMDA, and AURA HeadlinesRecent News About These CompaniesKamada (KMDA) is an Incredible Growth Stock: 3 Reasons WhySeptember 3 at 4:34 PM | msn.comWall Street Analysts See an 110.11% Upside in Kamada (KMDA): Can the Stock Really Move This High?September 3 at 10:56 AM | zacks.comKamada to Participate in Upcoming September Investor ConferencesSeptember 2 at 8:39 AM | finance.yahoo.comKamada Ltd. Engages Investors at September ConferencesSeptember 2 at 7:31 AM | tipranks.comKMDA or ARGX: Which Is the Better Value Stock Right Now?September 1, 2025 | zacks.comKamada Ltd’s Earnings Call: Positive Growth and Strategic InitiativesAugust 31, 2025 | tipranks.comKamada: Earnings Expansion Cycle With Embedded Margin Of SafetyAugust 27, 2025 | seekingalpha.comKamada (NASDAQ:KMDA) Stock Crosses Below 200-Day Moving Average - Here's What HappenedAugust 24, 2025 | marketbeat.comKamada Ltd. (NASDAQ:KMDA) Sees Significant Decline in Short InterestAugust 20, 2025 | marketbeat.com3 Reasons Growth Investors Will Love Kamada (KMDA)August 19, 2025 | msn.comKamada (NASDAQ:KMDA) Releases Earnings Results, Beats Expectations By $0.04 EPSAugust 17, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for Kamada FY2025 EarningsAugust 17, 2025 | marketbeat.comKamada Ltd. (NASDAQ:KMDA) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comWhat Makes Kamada (KMDA) a New Buy StockAugust 14, 2025 | msn.comKMDA vs. ILMN: Which Stock Is the Better Value Option?August 14, 2025 | zacks.comKamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...August 14, 2025 | finance.yahoo.comKamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to SayAugust 14, 2025 | msn.comKamada (KMDA) Q2 Earnings Top EstimatesAugust 13, 2025 | zacks.comKamada Q2 2025 Earnings PreviewAugust 12, 2025 | msn.com3KMDA : An Overview of Kamada's EarningsAugust 12, 2025 | benzinga.comKamada Ltd.: Kamada Announces FDA Approval of its Plasma Collection Center in Houston, TexasAugust 11, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAG, AUTL, KMDA, and AURA Company DescriptionsAdagene NASDAQ:ADAG$2.20 +0.06 (+2.80%) Closing price 03:58 PM EasternExtended Trading$2.30 +0.09 (+4.32%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Aura Biosciences NASDAQ:AURA$6.48 +0.06 (+0.93%) Closing price 04:00 PM EasternExtended Trading$6.33 -0.15 (-2.38%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Autolus Therapeutics NASDAQ:AUTL$1.46 +0.01 (+0.69%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.03 (+2.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Kamada NASDAQ:KMDA$7.14 +0.08 (+1.13%) Closing price 04:00 PM EasternExtended Trading$7.14 +0.00 (+0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
